What changed · written from our data
As of Nov 2, 2026Bambusa Therapeutics closed at $16.00 on Nov 2, up 6.74% — matching its highest close since Oct 30.
NASDAQ · BBTX
Bambusa Therapeutics, Inc. Common Stock (BBTX)
$16.00+6.74%
Close Nov 2, 2026 · split-adjustedNov 2, 2026$16.00▲ 6.74% in range
Oct 30, 2026Low $14.99 · High $16.00Nov 2, 2026
Market cap$796.2M49.8M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
Range since Oct 3014.99 – 16.000.0% from high
Volume433.2K
Volatility · 60d—Annualised
Short % of float—
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W —1M —3M —6M —YTD —1Y —3Y —5Y —Earnings reactions
History →No reported quarters with price history yet.
Rank within industry
Not enough peers to rank
6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—
Short interest
Details →No short interest reported.
News about Bambusa Therapeutics
All news →No recent articles focused on Bambusa Therapeutics.
Quick answers
- What does Bambusa Therapeutics do?
- Bambusa Therapeutics Inc is a clinical-stage biotechnology company developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases.
- What is BBTX's market cap?
- $796.19M, based on the Nov 2 close of $16.00.
About Bambusa Therapeutics
Bambusa Therapeutics Inc is a clinical-stage biotechnology company developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases.
Listed Oct 30, 2026bambusatx.com
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology